MARTIN CALIXTERIO: Open Payments
NPI 1538816939 · LOMA LINDA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,739 in 193 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $3,490 · 2025 $5,739
Food & beverage: $5,739
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 59 | $1,687 |
| Otsuka America Pharmaceutical, Inc. | 18 | $741 |
| Vanda Pharmaceuticals Inc. | 21 | $596 |
| Teva Pharmaceuticals USA, Inc. | 14 | $501 |
| Axsome Therapeutics, Inc. | 14 | $426 |
| E.R. Squibb & Sons, L.L.C. | 12 | $373 |
| Neurocrine BioSciences, Inc. | 11 | $353 |
| Janssen Pharmaceuticals, Inc | 7 | $284 |
| Lundbeck LLC | 10 | $159 |
| Alkermes, Inc. | 9 | $154 |
Products named: VRAYLAR, REXULTI, Auvelity, FANAPT, COBENFY, INGREZZA, AUSTEDO XR, UZEDY.
Industry payments across CA — which companies pay providers there.
